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Aims: To evaluate the effects of zinc with or without other antioxidants on blood glucose, lipid 
profile, and serum creatinine in adult diabetics on long-term follow-up.
Materials and methods: Patients (n = 96) were randomly allocated to three groups: group 
A (n = 29) was supplemented with oral zinc sulfate (22 mg/day) and multivitamin/mineral 
(zinc+MVM) preparation; group B (n = 31) was given the same preparation without zinc (MVM); 
and group C (n = 36) was given a matching placebo for a period of 4 months in a single-blinded 
study. Blood samples were taken at baseline and after 4 months of supplementation to assess 
blood glucose (fasting and postprandial) and glycosylated hemoglobin (HbA1C%) and serum 
levels of zinc, creatinine, and lipids.
Results: The zinc+MVM group had a mean change of fasting blood sugar −0.33 mmol/L 
(standard error of the mean 0.21 mmol/L) and was significant (P = 0.05) when compared 
with the other two groups (mean change in the MVM group +0.19 (0.31) mmol/L and +0.43 
(0.23) mmol/L in the control group, respectively). The HbA1C% level reduced significantly, 
irrespective of the baseline level, in zinc+MVM-supplemented individuals. In the other two 
groups, the change of HbA1C% level was not significant. Serum lipid levels reduced significantly 
in the zinc+MVM and MVM groups.
Conclusions: Zinc+MVM supplementation showed beneficial effects in the metabolic control 
of adult diabetics in addition to elevating their serum zinc level. Zinc supplementation improved 
glycemic control measured by HbA1C% and fasting and postprandial glucose. Furthermore, zinc 
supplementation lowered serum cholesterol and cholesterol/high-density lipoprotein ratio.
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Introduction
It has been known for decades that a physical–chemical relationship exists between 
insulin and zinc.1 Zinc was added in vitro to make protamine zinc insulin and lente 
crystalline insulin in order to prolong the duration of action of insulin by delaying its 
absorption from the subcutaneous injection site, thus requiring fewer insulin injections. 
Previous studies have shown that serum zinc level is lower in diabetes patients than 
in nondiabetes subjects, increased urinary zinc excretion being the main reason.2,3 
There are studies where zinc supplementation in diabetic patients shows antioxidant 
properties.4,5 In one study involving diabetics, zinc supplementation decreased lipid 
peroxidation.6 However, there are no prospective studies in type 2 diabetes patients 
on the association between serum zinc level and cardiovascular complications.
Glycemic control and prevention of secondary complications are the important 
goals of pharmacological therapy of diabetes mellitus. The inadequate efficacy of oral Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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hypoglycemic agents seen at times is attributed to inadequate 
  postreceptor events associated with   oxidative stress induced by 
long-term hyperglycemia. The administration of   antioxidants 
such as zinc, magnesium, selenium, vitamin A, and vitamin E 
may improve the tissue response to insulin and increase the 
efficacy of drugs that act through this   pathway. Elevated 
postprandial plasma levels of triglycerides (TG), free fatty 
acids, and cholesterol are common in type 2 diabetes.
To the best of our knowledge, there are no reports 
about the effects of zinc with or without other antioxidants 
(magnesium, selenium, vitamin A, and vitamin E) on blood 
sugar, serum insulin, lipid profile, and serum creatinine 
in adult type 2 diabetes patients already on standard 
medications. Coronary heart disease is a major cause of 
death in type 2 diabetes patients, and the risk of coronary 
heart disease is two- to four-fold higher among patients with 
type 2 diabetes than in nondiabetes subjects.7 This enhanced 
risk is partly explained by traditional cardiovascular risk 
factors, eg, hypertension, plasma lipid and lipoprotein 
abnormalities, smoking, and obesity, but all of the excess 
risk cannot be explained by these conventional risk factors. 
Therefore, this study was designed to determine the effects 
of zinc with or without other antioxidant supplementation 
among type 2 diabetes patients who were being followed 
up in medical clinics for more than 2 years in a tertiary 
care hospital.
Research design and methods
The study received approval from the Ethical Review 
  Committee of the Faculty of Medicine, University of Ruhuna, 
Galle, Sri Lanka. Previously diagnosed (for at least 2 years) 
patients with adult-onset (type 2) diabetes mellitus attending 
medical clinics of the teaching hospital in Karapitiya, Galle, 
were considered as the study population.
The following exclusion criteria were applied in selecting 
them:
1.  Those with renal or liver failure or any other chronic 
disease except essential hypertension and dyslipidemia
2.  Those who were taking vitamin–mineral supplements or 
any hormone replacement therapy
3.  Those with a history of recent surgery or acute infection
4.  Pregnant or lactating women
5.  Those who were receiving insulin preparations as a part 
of diabetes management.
All subjects (n = 96) were stratified by sex, age, and 
duration of treatment and randomly assigned to three 
treatment groups using the block randomization procedure. 
Group A (zinc+MVM) was supplemented with oral zinc 
sulfate (22 mg of elemental zinc/day) and a multivitamin/
mineral preparation (vitamin A, vitamin D3, vitamin E, 
  magnesium, manganese, copper, and selenium); group B 
(MVM) was supplemented with the same preparation but 
without zinc; and group C was supplemented with an 
identical placebo tablet. The study was registered at the 
Sri Lanka Clinical Trial Registry (SLCTR/2008/017) 
managed by the Sri Lanka Medical Association, linked to the 
Registry Network of the International Clinical Trials Registry 
Platform of the World Health Organization.
The composition of the supplement is given in Table 1. 
All subjects were instructed to take one tablet per day for 
a period of 4 months with their usual treatment regimen. 
The supplement and placebo tablets looked identical in 
color and shape. Because the reported mean daily intake of 
zinc in our population was low,8 the supplemented zinc dose 
was set at the recommended dietary intake (20–25 mg/day) 
for the Sri Lankan population. All other minerals and 
vitamins that were included in the tablet were more or 
less equal to the dietary reference intake levels set by the 
  Nutrition Coordination Division of the Ministry of Health, 
Sri Lanka.9
Once enrolled, all subjects were advised to attend 
a phlebotomy session at 08.00 after overnight fasting. 
A sample of 5 mL of venous blood was drawn before 
  taking any oral hypoglycemic agent(s) or other drugs and 
before aliquots were made for fasting blood sugar (FBS) 
and glycosylated hemoglobin (HbA1C%) in sugar and EDTA 
Table 1 nutrient composition of the preparation1
Vitamins
Vitamin A (as acetate) BP 5000.0 iU
Vitamin D3 (colecalciferol) BP 400.0 iU
Vitamin e (tocopheryl acetate) BP 151.0 iU
Thiamine nitrate BP 10.0 mg
Riboflavine BP 10.0 mg
Pyridoxine hydrochloride BP 2.0 mg
cyanocobalamin BP 7.5 μg
nicotinamide BP 50.0 mg
calcium pantothenate BP 10.0 mg
Ascoribic acid BP 75.0 mg
Minerals
Magnesium oxide BP 30 mg
Manganese sulfate BP 2.8 mg
copper sulfate BP 2 mg
Zinc sulfate monohydrate2 USP 63 mg
Selenium dioxide USP 70 μg
Notes:  1Group 1 subjects get the tablets prepared with full formulae, whereas 
group 2 subjects get the same without zinc sulfate monohydrate, and group 3 subjects 
get the placebo tablet consisting of filling base magnesium stearate. 2The elemental 
zinc content in the preparation was 22 mg.
Abbreviations: BP, British Pharmacopoeia; USP, United States Pharmacopeia.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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bottles, respectively. The remaining portion of the blood 
sample was centrifuged at 5000 rpm for 10 minutes, and 
serum was   separated and stored in acid-washed polystyrene 
tubes at −80°C until analysis for serum insulin, zinc, and 
creatinine was carried out. In addition, urine creatinine was 
measured from an aliquot of fresh urine sample obtained from 
each subject. Another portion of urine was stored at −80°C 
for analysis of urinary zinc. Following this, the patients 
were served with breakfast, and 2 hours later another blood 
sample (2 mL) was drawn for the assessment of postprandial 
blood sugar (PPBS). Another blood sample was collected 
on the next day after 14 hours of fasting for the assessment 
of lipid profile. Further, the patients’ dietary intakes were 
assessed using a 24-hour dietary recall questionnaire at the 
study entry.
The patients were advised to take the trial medication 
once daily with other medication, and a monthly follow-up 
was arranged. Clinicians were blinded to the trial medication 
and they were allowed to continue the usual care given 
for diabetes subjects during the trial period. The study 
subjects were receiving either a single oral hypoglycemic 
agent (either sulfonylurea or metformin) or a combination 
of metformin and sulfonylurea (Table 2). The common 
sulfonylureas that were prescribed included tolbutamide, 
glibenclamide, glipizide, and gliclazide. No patient was on 
acarbose or glitazone. No changes in pharmacological or 
nonpharmacological management occurred during the trial 
period. Compliance on the supplementation was assessed by 
counting the remaining tablets at weeks 4, 8, and 12, and all 
side effects of trial medication were noted. After 4 months 
of supplementation, blood and urine samples were collected 
under the same conditions as described before for the same 
biochemical analyses.
Laboratory analysis
The zinc content in serum and urine was measured using 
an enzyme-linked immunosorbant assay (ELISA) kit from 
BioAssay Systems, Hayward, CA, USA, by the quantitative 
Table 2 Baseline characteristics of the three study groups1,2
Parameter Zinc+MVM (n = 29) MVM (n = 31) Control (n = 36)
Age (yrs) 54.1 (6.0) 51.2 (6.0) 54.8 (8.0)
Weight (kg) 57.51 (9.83) 58.92 (11.61) 54.81 (10.47)
height (cm) 154.88 (8.34) 155.24 (8.69) 151.96 (8.06)
BMi (kg/m2) 23.89 (3.5) 24.64 (4.0) 23.71 (4.1)
Blood pressure
  Systole (mm hg) 122.96 (14.1) 121.92 (12.0) 123.33 (18.6)
  Diastole (mm hg) 76.67 (8.3) 74.69 (7.0) 77.00 (7.0)
Duration of treatment (yrs) 8.5 (2–24) 6.5 (2–25) 6.5 (2–25)
no. of hypoglycemic agents
  One 17 (59%) 19 (61%) 22 (61%)
  Two 12 (41%) 12 (39%) 14 (39%)
On cholesterol-lowering agents (statins)
  Yes 15 (52%) 17 (55%) 19 (53%)
  no 14 (48%) 14 (45%) 17 (47%)
On antihypertensive agents
  Yes 14 (48%) 12 (39%) 25 (69%)
  no 15 (52%) 19 (61%) 11 (31%)
On cardioprotective agents
  Yes 22 (76%) 16 (52%) 26 (72%)
  no 7 (24%) 15 (48%) 10 (28%)
Family history of diabetes
  Yes 16 (55%) 17 (55%) 19 (53%)
  no 13 (45%) 14 (45%) 17 (47%)
Dietary intake of (mg/d)
  energy (MJ/d) 5.24 (2.17) 5.18 (2.03) 5.21 (2.10)
  Zinc 3.54 (0.24) 3.86 (0.33) 4.42 (0.30)
  retinol 191.86 (41.03) 147.30 (23.50) 161.61 (18.41)
  Folate 77.30 (13.04) 69.24 (8.01) 75.10 (7.55)
  iron 18.74 (2.17) 18.83 (4.23) 22.19 (5.76)
  calcium 616.69 (58.17) 666.78 (51.06) 608.47 (40.82)
Notes: 1results presented as mean (standard deviation) except for the duration of treatment, which is given as mean (range). Treatment categories are given as number of 
subjects (%). 2There were no significant differences in age and anthropometric parameters between groups at the study entry.
Abbreviations: BMi, body mass index; MVM, multivitamin/mineral.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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colorimetric zinc determination at 425 nm.10 Serum insulin level 
was measured by an ELISA kit provided by BioSource Europe 
SA, Nivelles, Belgium.11 FBS and PPBS were enzymatically 
measured. HbA1C% was measured by chromatography method 
using a commercial kit (Sigma-Aldrich, St Louis, MO, USA). 
Serum TG and total cholesterol (TC) were enzymatically 
measured. High-density lipoprotein (HDL) cholesterol 
was determined after precipitation with phosphotungstate/
magnesium and low-density lipoprotein (LDL) cholesterol after 
precipitation with heparin/sodium citrate. Intra- and interassay 
coefficient of variation was ,5% for all laboratory tests.
Statistical analysis
The number of subjects per group was calculated based on the 
mean improvement in FBS (0.70 ± 1.10 mmol/L) shown by 
Farvid et al12 when supplemented with multivitamin–mineral 
supplementation. Twenty-five subjects per group would 
provide adequate power (80%) at the α error of 5% to detect 
the treatment effect of zinc supplementation. The number of 
patients per group was increased by 3 in each group with an 
assumption of a 10% dropout rate.
A one-sample Kolmogorov–Smirnov test was used to 
determine whether the baseline biochemical markers were 
normally distributed. Because the distributions of HbA1C%, 
serum TG, zinc, urine zinc, and creatinine values were 
skewed, they were log-transformed in all calculations. For 
presentation, these variables were transformed back to the 
original scale. The difference between the three groups at 
baseline was determined by one-way analysis of variance 
(ANOVA) for continuous data and the Chi-test for categorical 
data. Paired t-tests were used to study within-group treatment 
effects. The effect of intervention was determined by the 
univariate analysis repeated-measures design of the general 
linear model using SPSS Version 10.0 (SPSS Inc., Chicago, 
USA). Baseline values of respective parameters were also 
included in the analysis as a covariant for between-subject 
factors to correct for their possible confounding influence on 
the change in each parameter. Of the 96 subjects randomized, 
only 86 completed the study, and their data were included 
in the final analysis (per-protocol analysis). Spearman’s rho 
correlation was used to analyze the mean change of treatment 
effect with the respective baseline parameter. Two-tailed 
P , 0.05 was considered to be statistically significant.
Results
Baseline characteristics
Ninety-six diabetic individuals (33 males and 63 females) 
were recruited for the study. The baseline characteristics 
of the three groups are given in Table 2. There was no 
  difference in age distribution of patients in the three groups 
(males had a mean age of 54.6 ± 7.0 years whereas females 
had a mean age of 54.9 ± 9.0 years). Group A consisted of 
29 subjects (12 males), group B 31 subjects (11 males), and 
group C 36 subjects (10 males). However, only 86 patients 
completed the study (28 out of 29 subjects from group A, all 
31 subjects from group B, and 32 out of 36 from group C). Of 
the 10 patients who did not complete the trial, six were lost 
to follow-up, three did not take tablets for more than 2 weeks 
continuously, and diabetes treatment regimen was interrupted 
in the other individual. Those who completed the trial had drug 
compliance of .98%. The three groups were not different 
with regard to the use of lipid-lowering (statins) and other 
cardioprotective medications at the baseline or during the fol-
low-up. Further, dietary intake of trace mineral and vitamins 
was not different, and dietary zinc intake was 3.96 mg/day 
(standard deviation [SD] 1.68 mg/day) (Table 2).
effect on blood sugar levels
Compared with the baseline, the zinc+MVM group had a mean 
reduction of FBS of −0.33 mmol/L (standard error of the mean 
[SEM] 0.21 mmol/L) (P = 0.05). The FBS change observed in 
the MVM (+0.19 [0.31] mmol/L) and the control groups (+0.43 
[0.23] mmol/L) was not statistically significant (P = 0.89). 
The PPBS level also reduced significantly (P = 0.04) in the 
zinc+MVM group with a mean change of −1.55 (0.56) mmol/L 
after the intervention. The MVM group had a significant 
increase (P = 0.002) in HbA1C% level (+1.28 [0.21]%) from 
the baseline, whereas in the zinc+MVM group a significant 
reduction of HbA1C% was seen (−0.01 [0.25]%, P , 0.001) 
following intervention (Table 3). The mean changes observed 
in FBS, PPBS, and HbA1C% after supplementation were found 
to be negatively correlated with their respective baseline values 
of FBS (r = −0.46, P , 0.001), PPBS (r = −0.52, P , 0.001), 
and HbA1C%   concentration (r = −0.48, P , 0.001), raising 
the possibility of regression to mean effect in data. Data 
were reanalyzed using the “parameter estimate” function of 
univariate analysis of a general linear model where the final 
values were used as the dependent variable and the baseline 
values as a covariate. The observed β (mean difference) and 
the 95% confidence intervals for the three groups were more 
or less similar to the previous results.
Therefore, we categorized the subjects according to the 
degree of glycemic control (optimum control and partially 
controlled) based on their baseline levels of FBS, PPBS, and 
HbA1C, and the treatment effect was compared (Table 4). When 
the baseline FBS was ,5.56 mmol/L (,100.0 mg/dL), there was Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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no significant treatment effect with the intervention. However, 
when FBS was .5.56 (.100 mg/dL), supplementation, with 
or without zinc, showed a significant effect on FBS. In the 
zinc+MVM group, the FBS level dropped to 6.21 (0.85) 
mmol/L from the baseline 6.76 (0.58) mmol/L, whereas in 
the MV group the baseline FBS level of 6.96 (1.20) mmol/L 
dropped to 6.61 (1.07) mmol/L. When the PPBS level 
was .8.89 mmol/L (.160.0 mg/dL), all the groups showed 
a reduction in mean PPBS with the intervention (Table 4). 
The HbA1C% level reduced irrespective of the baseline levels 
in zinc+MVM-supplemented individuals. When the baseline 
HbA1C% level was ,6.0, the zinc+MVM group had a significant 
net reduction (mean level of 5.63 [0.15] at the baseline and 
5.53 [1.27] after the intervention, P , 0.05).
effect on serum insulin, zinc,  
and lipid profile
There was no significant effect on either serum or urine creatinine 
with the intervention (Table 3). There was a significant increase 
(mean change 12.44, SEM 1.3 μmol/L; P , 0.001) in serum 
zinc concentration in the zinc+MVM group, but there was no 
significant change in urinary zinc excretion, indicating that zinc 
supplementation improved only the body stores. Zinc+MVM 
and MVM supplementation had a significant effect on serum 
Table 4 effect of supplementation on blood sugar parameters1
Parameter Zinc+MVM MVM Control
Fasting blood sugar
Baseline , 100.0 mg/dL 
(,5.56 mmol/L)
 n 9 9 17
  Baseline 5.09 (0.43) 5.11 (0.47) 4.99 (0.6.0)
  Final 5.22 (1.22) 5.77 (1.28) 5.64 (1.25)
Baseline . 100.0 mg/dL 
(.5.56 mmol/L)
 n 19 17 15
  Baseline 6.76 (0.58) 6.96 (1.20) 7.00 (0.66)
  Final 6.21 (0.85)a 6.61 (1.07)a 7.17 (1.79)b
Postprandial blood sugar
Baseline , 160.0 mg/dL 
(,8.89 mmol/L)
 n 5 8 10
  Baseline 6.67 (1.00) 7.12 (0.66) 6.28 (1.22)
  Final 7.10 (1.43)a 8.51 (2.94)b 7.54 (1.81)c
Baseline . 160.0 mg/dL 
(.8.89 mmol/L)
 n 23 18 22
  Baseline 11.40 (1.81) 10.61 (1.42) 11.38 (2.07)
  Final 9.17 (1.62) 10.03 (1.84) 10.88 (3.18)
hemoglobin % (hbA1c%)
Baseline , 6.0
 n 10 11 12
  Baseline 5.63 (0.15) 5.81 (0.15) 5.81 (0.25)
  Final 5.53 (1.27)a 7.55 (1.20)b 6.29 (0.77)c
Baseline . 6.0
 n 18 15 20
  Baseline 7.79 (1.16) 7.75 (0.96) 7.49 (1.13)
  Final 6.78 (0.79)a 8.68 (1.15)b 7.66 (1.64)b
Notes: 1results expressed as mean (standard deviation). a,b,cSuperscripts within a 
row indicate significant difference (P , 0.05); univariate analysis.
Abbreviation: MVM, multivitamin/mineral.
Table 3 effect of supplementation on blood sugar and other 
serum/urine parametersa
Parameter Zinc+MVM  
(n = 28)
MVM  
(n = 26)
Control 
(n = 32)
Fasting blood  
sugar (mmol/L)
  Baseline
  Final
  Mean change
6.24 (0.94)
5.89 (1.07)
−0.33 (0.21)a
6.31 (1.31)
6.51 (1.13)
0.19 (0.31)b
5.92 (1.14)
6.36 (1.69)
0.43 (0.23)b
Postprandial blood  
sugar (mmol/L)
  Baseline
  Final
  Mean change
10.13 (3.03)
8.60 (1.93)
−1.55 (0.56)a
9.64 (2.14)
9.90 (2.18)
0.43 (0.50)b
9.58 (2.92)
9.84 (3.20)
0.05 (0.39)b
hemoglobin %  
(hbA1c)
  Baseline
  Final
  Mean change
7.50 (1.30)
6.64 (0.91)
−0.91 (0.25)a
6.84 (1.18)
8.20 (1.28)
1.28 (0.21)b
6.95 (1.20)
7.32 (1.58)
0.25 (0.23)c
Serum creatinine  
(μmol/L)
  Baseline
  Final
  Mean change
114.90 (45.21)
124.20 (42.59)
8.18 (9.45)
102.38 (26.00)
125.11 (36.04)
22.69 (9.70)
118.15 (33.14)
135.00 (34.87)
15.94 (7.72)
Serum insulin  
(μmol/L)
  Baseline
  Final
  Mean change
57.90 (12.92)
55.53 (13.20)a
−2.01 (2.87)
52.88 (15.21)
52.52 (9.54)a
−1.22 (1.87)
55.18 (21.53)
46.57 (18.15)b
−8.11 (3.44)
Serum zinc  
(μmol/L)
  Baseline
  Final
  Mean change
9.33 (7.64)
21.98 (9.99)a
12.44 (1.30)a
9.77 (7.31)
10.99 (7.54)b
0.45 (0.72)b
11.51 (7.72)
9.97 (7.11)b
−1.86 (0.71)b
Urine creatinine  
(μmol/L)
  Baseline
  Final
  Mean change
89.72 (52.06)
105.93 (71.11)
16.41 (14.70)
84.42 (36.30)
104.00 (61.65)
19.00 (12.75)
91.72 (59.92)
106.31 (48.20)
15.63 (11.72)
Urinary zinc  
(μmol/L)
  Baseline
  Final
  Mean change
1.71 (1.29)
1.89 (1.37)
0.16 (0.41)
2.11 (1.97)
1.70 (1.57)
−0.62 (0.47)
1.83 (1.47)
2.01 (1.68)
0.08 (0.37)
Notes: 1results expressed as mean (standard deviation) except for mean change 
mean (standard error of the mean). Only those who had completed the trial (n = 86) 
were  included  in  the  analysis.  a,b,cSuperscripts  within  a  row  indicate  significant 
difference  (P  ,  0.05);  univariate  analysis  with  baseline  value  of  the  respective 
parameter was included as a cofactor.
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lipids (Table 5). TC level in the zinc+MVM group dropped 
from 4.51 (0.99) mmol/L at baseline to 3.73 mmol/L after 
4 months of intervention (P , 0.05). In the MVM group, TC 
level dropped from 4.36 mmol/L at the baseline to 4.22 (0.47) 
mmol/L (P , 0.05). Although a reduction in TG level was 
seen in all three groups, only in the MVM group did the change 
reach statistical significance (mean change of −0.07, SEM 
0.08 mmol/L, P , 0.05). LDL cholesterol level also reduced 
in the zinc+MVM group from 2.60 (0.84) mmol/L to 2.54 
(0.77) mmol/L (P , 0.05). Furthermore, cholesterol:HDL ratio 
reduced in both the zinc+MVM (from 3.39 to 3.21, P , 0.05) 
and MVM (from 3.37 to 3.20, P , 0.05) groups, whereas in 
the placebo group the baseline ratio of 3.42 increased to 3.92 
(P , 0.05) after the intervention.
Discussion and conclusion
Previous research suggests that homeostasis of essential 
trace elements, especially zinc, can be disrupted by   diabetes 
mellitus.5,13 Our data showed that zinc supplementation causes 
an increase in serum zinc level, as reported in other studies.14,15 
Vitamins and minerals play diverse roles in the human 
body, not only in preventing deficiency diseases but also 
in regulating metabolism, gene expression, and influencing 
the development and progression of many chronic diseases. 
There is experimental and clinical evidence, especially in 
developed countries, supporting an alteration of zinc metabo-
lism in patients with diabetes.1,16 However, only a few studies 
have examined the relationship between zinc and diabetes in 
developing countries.17 The mean serum zinc level in healthy 
individuals has varied from 11.4 μmol/L to 17.8 μmol/L.18 
A study in Iran by Al-Maroof and Al-Sharbatti19 reported a 
lower mean serum zinc value (9.40 μmol/L) among diabetes 
patients. We observed a mean zinc level of 10.29 μmol/L 
(SD 7.50 μmol/L) in 96 diabetes patients who have been on 
treatment over a period ranging from 2 years to 22 years. This 
is lower than that (11.30 μmol/L) reported in a study of 110 
Tunisian adult diabetics (both type 1 and type 2).5 When the 
cutoff level of ,10.7 μmol/L was used to define zinc defi-
ciency, 65% (n = 63) of patients had serum zinc levels below 
this cutoff level in our study. However, we did not consider 
serum measurements of different antioxidants in the supple-
mentation, as their effectiveness has already been proven.4,5
We  observed  that  group A  had  a  mean  change 
of −0.33 mmol/L in blood glucose level, whereas group C 
  (placebo-controlled group) had a +0.43 mmolL change in blood 
glucose after 4 months of supplementation.   Therefore, we can 
speculate that, overall, there is a 0.76 mmol/L (14 mg/100 mL) 
difference with zinc+MVM supplementation among diabetes 
patients. Further, we have shown that zinc supplementation 
(with or without other MVM) was effective in reducing FBS 
in partially controlled adult diabetics (FBS . 100 mg/dL) who 
were on long-term follow-up. Furthermore, supplementation 
significantly improved PPBS and HbA1C% levels when com-
pared with placebo. This was similar to the results reported 
by   Hussain et al20 that showed a 25% reduction in FBS and 
a 17%   reduction in HbA1C% with 3 months’ supplementation 
with zinc and melatonin. In our analysis, the mean HbA1C% 
of the supplemented groups (zinc+MVM and MVM groups) 
reduced significantly by 0.3 ± 0.8% at the end of 4 months 
of follow up, whereas no significant change was found in the 
control group. The significant changes observed in the supple-
mented groups refer to the effective improvement in their 
glycemic control in response to zinc and other multivitamin 
and   mineral supplementation. Our observations are consistent 
with the results of other trials that examined the effect of zinc 
supplementation on patients with type 2 diabetes.5,19
The significant negative correlation we observed between 
the change in serum zinc level after supplementation and 
the baseline serum zinc level suggests that zinc-deficient 
  individuals had greater absorption of zinc than individuals 
with higher zinc levels at the baseline. This finding is 
Table 5 Supplementary effects on lipid profile of study subjects1
Parameter Zinc+MVM  
(n = 28)
MVM  
(n = 26)
Control  
(n = 32)
Total cholesterol  
(mmol/L)
  Baseline 4.51 (0.99) 4.36 (0.82) 4.48 (0.96)
  Final 3.73 (0.88)a 4.22 (0.47)a 4.82 (0.98)b
  Mean change −0.79 (0.16)a −0.17 (0.17)b 0.26 (0.18)b
Triglycerides (mmol/L)
  Baseline 1.06 (0.51) 1.34 (0.58) 1.24 (0.51)
  Final 1.04 (0.31)a 1.30 (0.56)b 1.23 (0.43)a
  Mean change −0.02 (0.09) −0.07 (0.08) −0.02 (0.07)
high-density lipoprotein  
(mmol/L)
  Baseline 1.35 (0.22) 1.30 (0.19) 1.33 (0.19)
  Final 1.45 (0.31)a 1.34 (0.24)a 1.25 (0.18)b
  Mean change 0.10 (0.06)a 0.04 (0.06)a −0.08 (0.05)b
Low-density lipoprotein  
(mmol/L)
  Baseline 2.60 (0.84) 2.45 (0.73) 2.63 (0.88)
  Final 2.54 (0.77)a 2.53 (0.55)b 2.97 (0.87)
  Mean change −0.06 (0.13) 0.09 (0.16) 0.26 (0.13)
ratio
  Baseline 3.39 (0.74) 3.37 (0.59) 3.42 (0.75)
  Final 3.21 (0.50)a 3.20 (0.40)a 3.92 (0.93)b
  Mean change −0.72 (0.18)a −0.20 (0.17)b 0.44 (0.18)c
Notes: 1results expressed as mean (standard deviation) except for mean change mean 
(standard error of the mean); ratio = cholesterol/high-density lipoprotein. a,b,cSuperscripts 
within a row indicate significant difference (P , 0.05); univariate analysis.
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  consistent with the results of other studies, suggesting 
that zinc treatment will have a high chance of success in 
  changing zinc status in zinc-deficient subjects.21 In addition, 
we observed that baseline serum insulin levels were positively 
correlated with final serum insulin levels and negatively with 
mean change after the intervention (data not shown). Previ-
ous studies examining the effect of zinc supplementation on 
insulin level are sparse. Hussain et al20 found no change in 
serum C-peptide level with zinc supplementation. However, 
we require studies with longer follow-up to see whether an 
increase in insulin secretion is sustained over a longer time 
period. Zinc treatment has also been shown to raise body 
defenses in immune-suppressed patients.22 It is important to 
note that a large proportion of subjects in our study had a low 
serum zinc level at the baseline and that daily administration 
of zinc for 4 months resulted in almost double the baseline 
value (mean improvement + 12.44 μmol/L). We have not 
addressed issues related to immune status in the current study, 
and the clinical importance of the high prevalence of zinc 
deficiency among adult diabetics is not known to us.
Treatment with MVM with or without zinc reduced TC, 
TG, and LDL plasma levels and increased HDL   levels. These 
observations are consistent with those reported by Kadhim 
et al,23 whereby a group of poorly controlled   diabetes patients 
were supplemented with zinc and melatonin for a period of 
3 months. In the current study, we observed a significant 
decrease in TG concentration (mean change of −0.07 mmol/L; 
P , 0.05) only in the MVM group. Partida-Hernández et al,24 
however, showed a significant decrease in TG concentration 
following 12-week supplementation with 100 mg zinc sul-
fate among diabetics who were not on cholesterol-lowering 
treatment. Furthermore, they showed a significant reduction 
in TC and an increase in HDL   cholesterol, indicating that 
supplementation, in addition to improving glycemic indices, 
has favorable effects on other cardiovascular risk factors. 
Even though we have shown a similar trend, the reduction 
in TC and the effect on HDL levels were not as great as they 
reported. Most of our patients were already on cholesterol-
lowering drugs and, as such, they may have achieved the 
“desired” lipid targets at the study entry.
Garber and Karlsson25 showed that the treatment of 
dyslipidemia in diabetes must be focused on several targets 
involving glycemic control and reduction of LDL levels. 
The results of the present study are agreeable with these 
suggestions. There is evidence suggesting that zinc can act 
as an endogenous protective factor against atherosclerosis by 
inhibiting the oxidation of LDL in the presence of transition 
metals,26 and that adequate zinc nutrition may protect against 
inflammatory diseases such as atherosclerosis by inhibiting 
the activation of oxidative stress responsive transcription 
  factors as well as the expression of inflammatory cytokines.
The present intervention did not show any significant 
effect on renal functions measured by serum as well as 
urine creatinine, and our observations are similar to those of 
Khadim et al.23 In contrast, a significant improvement in renal 
function has been observed in a previous study27 after 60 days 
of supplementation. One limitation of our study is that we did 
not measure urinary microalbumin levels of the patients.
We performed this study in a single-blinded manner for 
logistical reasons, and this may have reduced the validity of 
data. This is one of the limitations in the study, as expectation 
bias or change in the behavior of the study subjects may have 
affected the results. However, only the FBS results were given to 
the clinicians at the follow-up sessions of their respective clinics. 
Secondly, we did not measure the change in physical activity 
and anthropometry because of the short duration (4 months) of 
follow-up. Therefore, we were unable to comment on the effect 
on anthropometry (ie, body mass index) with the intervention. 
Further, the small sample size may have contributed to incon-
clusive results seen in some analyses. To minimize the effects 
of disparity in baseline values between groups (ie, high HbA1C% 
levels in the zinc+MVM group over the other two groups), we 
included baseline measurements in each analysis as a   cofactor 
(see Statistical analysis). Although physicians were free to 
make changes in the management of these patients, no changes 
in the major drugs such as antidiabetics, antihypertensives, or 
lipid-lowering therapy were made during the trial period. Apart 
from the trial drug, we inquired about the patients’ compliance 
to their regular medication as well. However, there is still a pos-
sibility that patients may have changed their behavior (ie, diet 
and physical activity)   during the trial period, but we expected 
it to be uniform in all three groups. This altered behavior can 
considerably limit the study outcome.
Data on dietary intake or serum zinc levels are limited to 
young children and adolescents8,28 in Sri Lanka. Baines and 
Roberts29 have reported that if the intake of zinc is marginal, 
it can have a major impact on food intake by reducing taste 
sensation. As taste is already impaired in the elderly, this 
can seriously affect food choice. Zinc is readily available 
in animal foods, especially red meat, liver, fish, and eggs. 
If this is not feasible, then the use of a multivitamin and 
minerals supplement may be a suitable alternative. However, 
multiple medication use is prevalent in this population, and 
another pill may add to the confusion.
In conclusion, the supplementation of zinc with other 
multimineral vitamins daily for a period of 4 months to adult Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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diabetes patients on standard diabetic care demonstrated 
favorable changes in metabolic profile, including better 
  glycemic control and desirable changes in lipid profile. Based 
on the results presented in this report, it can be concluded 
that zinc, either alone or in combination with other known 
antioxidant minerals and vitamins, may have supplementary 
benefits in the routine management of adult diabetes.
Future applications
This study needs to be reproduced to examine the effect of 
zinc and other multimineral vitamins on long-term diabetic 
control, complications, and morbidity. Furthermore, the 
ability of zinc supplementation to reverse the components 
of metabolic syndrome should be examined.
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